Effect of intra-partum Oxytocin on neonatal encephalopathy: a systematic review and meta-analysis

BackgroundDespite a global decreasing trend in neglected tropical diseases (NTDs), progress is not on track to meet the Sustainable Development Goals by 2030. Evidence suggests a positive effect of conditional cash transfer programs on controlling NTDs. However, it remains to be evaluated whether other financial incentive programs exert similar effects on NTD-related service utilization and treatment outcomes in low- and middle-income countries (LMICs).ObjectiveThis systematic review aims to evaluate the effects of cash transfer and incentive programs on NTD-related service utilization and treatment outcomes in LMICs; to examine how covariates, program design, and implementation plan influence these outcomes; and to examine how NTD-related service utilization and treatment outcomes influence nutritional status and health in LMICs.MethodsThis review will follow the PICOS (Population, Interventions, Comparators, Outcomes, Study Design) framework. The population of this review will be restricted to adults and children of all ages in LMICs. For intervention selection, we will include any program or policies addressing socioeconomic disadvantage through the provision of cash transfers or incentive programs, including but not limited to in-kind transfers, food vouchers, free medicine vouchers, discount coupons, and microcredit to households or individuals. Eligible comparators will be the population who did not receive any intervention, recipients of interventions from before the intervention, and populations or areas exposed to different levels of intervention coverage. The primary outcomes will be service utilization and treatment outcomes related to any of the 21 NTDs prioritized by the World Health Organization. Studies without any financial incentive intervention will be excluded. Studies available in English between 2000 and 2024 will be searched in databases, including PubMed, Google Scholar, Scopus, Cochrane, Embase, and CINAHL. Screening, data extraction, and risk of bias assessment will be conducted independently by two reviewers, and discrepancies, if any, would be resolved by a third reviewer. Quality assessment will use the Revised Cochrane Risk of Bias for randomized trials (RoB 2), Risk of Bias in Non-Randomized Studies of Interventions (ROBINS-I), the Joanna Briggs Institute (JBI) checklist for cross-sectional studies, and the Critical Appraisal Skills Programme (CASP) tool for qualitative studies. Data synthesis will involve narrative summaries by tables and figures, a meta-analysis will be undertaken, and subgroup analyses will be performed where feasible.ResultsThis project is supported by the Children’s Investment Fund Foundation and was funded in March 2024. As of January 15, 2026, article search and title-abstract screening have been completed, and full-text screening is expected to be completed by February 2026. Findings will then be synthesized and reported by the end of April 2026.ConclusionsThe limitations of the study may include potential language bias and methodological heterogeneity, which may limit the feasibility of meta-analysis. The findings of this review will inform policymakers in developing more effective strategic plans for controlling NTDs in LMICs.

This systematic review aimed to assess the efficacy and safety of Drospirenone and Ethinylestradiol Tablets (II) in the treatment of dysmenorrhea. Electronic databases, namely PubMed, Embase, Cochrane Controlled Register of Trials (CENTRAL), Scopus, Science, CBM, CNKI, Wanfang, and VIP, were searched before September 2022. Randomized controlled trials (RCTs), non-randomized controlled trials, cohort studies, case-control studies, and single-arm studies were included. Furthermore, the Cochrane Risk of Bias Tool for Systematic Reviews version 1 was used for the risk of bias assessment on RCTs. The Risk of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool was used for risk of bias assessment on non-randomized studies. The risk ratio (RR) was calculated for dichotomous data. Mean difference (MD) or standardized MD (SMD) were used as the effect size for continuous data. A total of 11 studies involving 2,251 participants with dysmenorrhea were included. When Drospirenone and Ethinylestradiol Tablets (II) conventional 24/4-day regimen was compared with placebo, the total efficiency rate (defined as pain symptom disappearing or being relieved) in Drospirenone and Ethinylestradiol Tablets (II) 24/4-day regimen group was higher than in placebo group (RR = 5.55, 95%CI: 2.48-12.39, P < 0.0001). No clear differences were found on risk of overall adverse events or specific adverse events. When Drospirenone and Ethinylestradiol Tablets (II) was compared with active control drugs, no clear differences were found on the total efficiency rate or visual analog scale (VAS) scores for dysmenorrhea and other related pain. The risk of overall adverse events decreased in Drospirenone and Ethinylestradiol Tablets (II) conventional 24/4-day regimen (13/53 vs. 66/148, RR = 0.55, 95%CI: 0.33-0.91) when compared with active control drugs group. When Drospirenone and Ethinylestradiol Tablets (II) flexible extended regimen was compared with conventional 24/4-day regimen, the number of days of dysmenorrhea (MD=-3.98, 95%CI: -5.69 to -2.27), and dysmenorrhea associated with unscheduled bleedings (MD = -1.6, 95%CI: -2.8 to -0.5), were fewer in flexible extended regimen. In addition, there were no differences found on risk of adverse events (including mood changes, spotting, headache, breast pain, nausea, and vomiting) between compared groups (P > 0.05). Drospirenone and Ethinylestradiol Tablets (II) could improve symptoms of dysmenorrhea and decrease other related pain symptoms. More high-quality evidence is needed to confirm the advantages. [https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021271605], identifier [CRD42021271605].

Previous reviews have investigated the relationship between empathy and burnout. However, these are now out of date, did not capture the effect of the pandemic, did not include healthcare professionals other than doctors and nurses or medical students, did not assess the impact of differences in profession and did not pool the data, which made estimating the strength of the association unclear. We therefore aim to address these shortcomings in an up-to-date, rigorous, systematic review and meta-analysis. Findings will be reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines and flowchart.We will search American Psychological Association (APA) PsycINFO, APA PsycArticles, Cumulative Index to Nursing and Allied Health Literature (CINAHL), The Cochrane Library, PubMed and Scopus. We will also search ResearchSquare and Social Science Research Network (SSRN) for preprints; ProQuest Dissertations and Theses and Electronic Theses Online Service for relevant theses. Forward and backward citation searches will identify additional studies. Two independent reviewers will screen titles, abstracts and full texts and extract data. Two independent reviewers will assess risk of bias using Risk of Bias 2 (RoB 2) for randomised controlled trials, Risk of Bias in Non-randomised Studies of Interventions (ROBINS-I) for non-randomised interventional studies and Risk of Bias in Non-randomised Studies of Exposures (ROBINS-E) for observational studies.For all included studies, we will summarise the study characteristics, including number of participants; health profession, specialty and career stage; country and gender. If data are suitable, we will pool results and conduct subgroup analyses (including by health profession, career stage and clinical specialty). We will also explore the relationships between subscales of empathy and burnout. We will use metaregression to explore the impact of theoretically derived factors (such as study design and profession) on the strength of the association. Sensitivity analyses will assess the impact of low-quality research. In our discussion, we will summarise results, the limitations and provide a general interpretation of the results and implications. Ethical approval is not required for this review, as primary data will not be collected. The review will be disseminated through peer-reviewed publication and presentation at conferences. CRD420251075618.

Childhood cancer outcomes in low- and middle-income countries (LMICs) lag behind those in high-income countries (HICs), in part due to late presentation and diagnosis. Though several interventions targeting early detection of childhood cancer have been implemented in LMICs, little is known about their efficacy. We conducted a systematic review to identify studies describing such interventions. We searched multiple databases from inception to December 4, 2019. Studies were included if they reported on LMIC interventions focused on: (a) training of health care providers on early recognition of childhood cancer, or (ii) public awareness campaigns. We used preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines to conduct our review. The risk of bias in nonrandomized studies of interventions (ROBINS-I) checklist was used to assess quality of studies. Twelve studies met inclusion criteria (n=5 full text, n=7 abstract only). Five studies focused on retinoblastoma only, while the others focused on all types of childhood cancer. The majority studied multiple interventions of which early detection was one component, but reported overall outcomes. All identified studies used pre-post evaluative designs to measure efficacy. Five studies reported statistically significant results postintervention: decrease in extraocular spread of retinoblastoma, decrease in rates of refusal/abandonment of treatment, increase in number of new referrals, increase in knowledge, and an absolute increase in median 5-year survival. Other studies reported improvements without tests of statistical significance. Two studies reported no difference in survival postintervention. The ROBINS-I checklist indicated that all studies were at serious risk of bias. Though current evidence suggests that LMIC interventions targeting early detection of childhood cancer through health professional training and/or public awareness campaigns may be effective, this evidence is limited and of poor quality. Robust trials or quasi-experimental designs with long-term follow up are needed to identify the most effective interventions. Such studies will facilitate and inform the widespread uptake of early detection interventions across LMIC settings.

IntroductionHuman papillomavirus (HPV) is a major global health concern linked to cancers. Although a safe and effective vaccine exists, HPV vaccination rates are still low among Asian American and Pacific Islander (AAPI) populations. Barriers such as limited awareness, cultural stigma and systemic inequities contribute to this gap. This systematic review and meta-analysis aims to compile current evidence on HPV vaccination behaviours and related factors among AAPIs to help develop culturally tailored interventions and public health strategies.Methods and analysisThis review will include descriptive and correlational studies (quantitative, qualitative and mixed methods), examining HPV vaccination intention or uptake among AAPI populations in the USA from inception to December 2024. Randomised controlled trials and intervention studies will be excluded. Databases to be searched include PubMed, CINAHL, PsycINFO and Cochrane. Study screening, data extraction and quality assessment will be conducted independently by three reviewers using standardised tools. Risk of bias in non-randomised studies will be assessed using Risk Of Bias In Non-randomised Studies of Interventions (ROBINS-I), and the Critical Appraisal Skills Programme (CASP) checklist will be used for qualitative studies. Quantitative findings will be synthesised narratively and, where appropriate, through meta-analysis using random-effects models. Qualitative themes will be synthesised to contextualise quantitative results.Ethics and disseminationEthics approval is not required for this protocol as it does not involve primary data collection. Findings will be disseminated via peer-reviewed publications and conference presentations. Findings of this systematic review and meta-analysis will provide critical insights for promoting HPV vaccination and reducing HPV-related cancer disparities among AAPIs.PROSPERO registration numberCRD420251008431.

A systematic review showed more consideration is needed when conducting nonrandomized studies of interventions

IntroductionMetallic and elastomeric ligatures are widely used in orthodontics to secure the archwire within the bracket slots, but elastomeric ligatures have traditionally been associated with increased microbial colonization, which could adversely affect periodontal health.AimThis systematic review compares the periodontal effects of elastomeric and steel ligatures used for orthodontic fixed appliances.MethodsUnrestricted literature search of 7 databases (MEDLINE, Scopus, Web of Science, Embase, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, and Virtual Health Library) up to July 2023 were performed for randomized / non-randomized clinical studies on humans comparing the two ligation methods during fixed-appliance therapy. After duplicate study selection, data extraction, and risk-of-bias assessment with the Risk of Bias (RoB) 2 or the Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool, random-effects meta-analyses of Mean Differences (MD) or Standardized Mean Differences (SMD) and their 95% confidence intervals (CIs) were carried out, followed by assessment of certainty of existing evidence with the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach.ResultsA total of 11 studies (3 randomized / 8 non-randomized) with 354 patients (mean age 14.7 years and 42% male) were included. No statistically significant differences were seen for plaque index (5 studies; SMD = 0.48; 95% CI = -0.03 to 1.00; P = 0.07), gingival index (2 studies; MD = 0.01; 95% CI = -0.14 to 0.16; P = 0.89), probing pocket depth (2 studies; MD = 0; 95% CI = -0.17 to 0.16; P = 0.97), or Streptococcus mutans counts (4 studies; SMD = 0.40; 95% CI=-0.41 to 1.20; P = 0.21). Elastomeric ligatures were associated with moderately increased total bacterial load (3 studies; SMD = 0.43; 95% CI = 0.10 to 0.76; P = 0.03). Confidence in these estimates was low in all instances due to the inclusion of non-randomized studies with high risk of bias.ConclusionsExisting low quality evidence indicates that ligature method does not seem to influence the periodontal health during fixed treatment, even if elastomeric ligatures are associated with a moderate increase of bacterial load.RegistrationPROSPERO (CRD42023444383)

Non-ventilator healthcare-associated pneumonia (NV-HAP), a subset of healthcare-associated pneumonia (HAP), is common and significantly increases patient mortality and hospital stay. However, no systematic review has been undertaken to synthesise the impact of NV-HAP on these outcomes. The aim of this study was to undertake a review of the evidence on the impact of NV-HAP on mortality and additional length of stay in adults admitted to an acute care hospital. We performed a systematic search to identify research exploring and evaluating the impact of NV-HAP on mortality and additional length of stay in adults admitted to an acute care hospital. The electronic databases MEDLINE and CINAHL were searched, for peer-reviewed articles published between January 2004 and August 2025. An assessment of the study quality and risk of bias of included articles was conducted using the ROBINS-E (Risk of Bias in Non-randomized Studies - of Exposures) and ROBINS-I (Risk of Bias in Non-randomized Studies - of Interventions) tool. A total of 6324 studies were initially identified, with 49 articles included in the review following the screening and full-text review. Twenty-six papers identified both mortality and additional length of stay results, 21 papers identified mortality results only and two papers reported additional length of stay results only. Inpatient mortality following NV-HAP ranged from 3.1 to 73.9%. Additional length of stay associated with NV-HAP was extended between 10 and 47.5 days. This systematic review highlights the impact of NV-HAP on patients admitted to hospital. NV-HAP was associated with patient mortality and additional length of stay. Results of this study will inform a larger planned program of research.

Constructed communication models, including SBAR (Situation, Background, Assessment, Recommendation), SOAP (Subjective, Objective, Assessment, Plan), and PIE (Problem, Intervention, Evaluation), have become more and more significant in the field of nursing because of improving handoff communication and ensuring patient safety. The purposes of these documentation formats are to achieve consistency in sharing information, keep to a minimum the occurrence of errors, and enhance the concreteness and effectiveness of communication between healthcare professionals.The systematic review was conducted to determine how the SBAR, SOAP, and PIE models can help to enhance the quality of the handoff process, alleviating the number of clinical errors and ensuring the safety of patients in different clinical contexts. The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. A comprehensive literature search was performed across PubMed, Web of Science, and the Cochrane Library using a combination of text words and controlled vocabulary. Studies published in English between January 2005 and May 2025, involving registered nurses and nursing staff in hospital or inpatient settings, were included. Only quasi-experimental studies, randomized controlled trials, and mixed-method studies were considered. Risk of bias was assessed using the Cochrane Risk of Bias (RoB) 2.0 for randomized controlled trials and the Risk of Bias In Non-randomized Studies of Interventions (ROBINS-I) for non-randomized studies, and the methodological quality of mixed-method studies was appraised with the Mixed Methods Appraisal Tool (MMAT). Risk of bias figures were visualized using the robvis tool.A total of 15 studies met the inclusion criteria. The quality of the 15 included studies ranged from moderate to high. Findings demonstrated that structured documentation frameworks significantly improve communication clarity, reduce information omissions, enhance documentation accuracy, and lower the incidence of handoff-related errors.SBAR was particularly effective in high-acuity settings, while SOAP and PIE were beneficial in routine care and ongoing patient assessment. Overall, the implementation of structured nursing documentation enhances interdisciplinary collaboration, supports safer transitions of care, and contributes to improved patient outcomes.

Introduction Vitiligo is a chronic autoimmune depigmenting disorder. Ruxolitinib 1.5% cream is currently the only therapy specifically approved for its treatment. In addition, clinical guidelines recommend off label standard therapies, including topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), phototherapy (narrowband UVB or excimer devices), and selected off-label systemic regimens. Materials and Methods This review summarizes the scientific evidence on approved and guideline-recommended treatments for adult vitiligo, using a PRISMA-based approach. Only English-language articles published between 2000 and 2025 were included. Interventions comprised approved therapies and standard treatments recommended by guidelines. Outcomes evaluated were changes in Facial and Total Vitiligo Area Scoring Index (F-VASI/T-VASI), quality of life, and safety. Risk of bias was assessed using the Risk of Bias 2 (RoB 2) tool for randomized controlled trials (RCTs) and the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) for non-randomized studies. Results Ruxolitinib cream demonstrated superior F-VASI responses compared with vehicles in phase II–III RCTs. Evidence supports the efficacy of potent or very potent TCS, TCI, and NB-UVB or targeted 308-nm devices in localized disease. Conclusion Systemic regimens show benefits in selected clinical scenarios, although supporting evidence remains heterogeneous. Treatment selection should be individualized based on disease activity, extent, anatomical site, and patient preferences.

Microimplant-assisted rapid palatal expansion is increasingly used clinically; however, the effect on the upper airway volume in patients with maxillary transverse deficiency has not been thoroughly evaluated yet. The following electronic databases were searched up to August 2022: Medline via Ovid, Scopus, Embase, Web of Science, Cochrane Library, Google Scholar, and ProQuest. The reference lists of related articles were also reviewed by manual search. The Revised Cochrane Risk of Bias Tool for randomized trials (ROB2) and the Risk of Bias in non-randomized Studies of Interventions (ROBINS-I) tool were used to evaluate the risks of bias of the included studies. The mean differences (MD) and 95% confidence intervals (CI) of changes in nasal cavity and upper airway volume were analyzed using a random-effects model, and subgroup and sensitivity analyses were also performed. Two reviewers independently completed the process of screening studies, extracting data, and assessing the quality of studies. In total, twenty-one studies met the inclusion criteria. After assessing the full texts, only thirteen studies were included, with nine studies selected for quantitative synthesis. Oropharynx volume increased significantly after immediate expansion (WMD: 3156.84; 95% CI: 83.63, 6230.06); however, there was no significant change in nasal volume (WMD: 2527.23; 95% CI: −92.53, 5147.00) and nasopharynx volume (WMD: 1138.29; 95% CI: −52.04, 2328.61). After retention a period, significant increases were found in nasal volume (WMD: 3646.27; 95% CI: 1082.77, 6209.77) and nasopharynx volume (WMD: 1021.10; 95% CI: 597.11, 1445.08). However, there was no significant change after retention in oropharynx volume (WMD: 789.26; 95% CI: −171.25, 1749.76), palatopharynx volume (WMD: 795.13; 95% CI: −583.97, 2174.22), glossopharynx volume (WMD: 184.50; 95% CI: −1745.97, 2114.96), and hypopharynx volume (WMD: 39.85; 95% CI: −809.77, 889.46). MARPE appears to be linked with long-term increases in nasal and nasopharyngeal volume. However, high-quality clinical trials are required to further verify the effects of MARPE treatment on the upper airway.

The aim of this study was to systematically review the ability of resin infiltration to conceal demineralized enamel lesions to normal enamel translucency and to maintain color stability. A literature search of PubMed, MEDLINE, Web of Science, and Scopus databases and a manual search of articles from 2009 to 2021 for randomized controlled trials (RCTs) and clinical efficacy trials (nonrandomized) were performed. Methodological quality and risk of bias (RoB) of included papers was assessed using Cochrane Collaboration Risk of Bias Tool 2.0 for RCTs and ROBINS-I (Risk Of Bias In Non-randomized Studies of Interventions) tool for nonrandomized studies. A total of 352 titles and abstracts were reviewed. Eight RCTs and three clinical efficiency studies were included in this review. The masking effects of the demineralized enamel lesion were reported immediately after resin infiltration, and the color stability of this material was up to 24 months, with no adverse effects noted. For RCTs, four studies were classified as "some concerns" and four were as "low RoB." For nonrandomized studies, all of the studies presented an overall moderate RoB. Resin infiltration achieves the best esthetic outcomes compared with microabrasion and remineralization therapy. Color stability was achieved with this material for up to 24 months and no adverse effects were noted. Factors contributing to the esthetic outcomes of the resin include the elimination of the hypermineralized surface layer, the homogeneity of the resin itself, and polishing after resin infiltration. Longitudinal follow-up and improved control of confounding variables should characterize future high-quality systematic reviews.

Efficacy of Intravitreal Injections Anti-Vascular Endothelial Growth Factor Treatment for Radiation Retinopathy: A Systematic Review and Meta-analysis

Levetiracetam is commonly used for seizure prophylaxis in patients with intracerebral hemorrhage (ICH), traumatic brain injury (TBI), supratentorial neurosurgery, and spontaneous subarachnoid hemorrhage (SAH). However, its efficacy, optimal dosing, and the adverse events associated with levetiracetam prophylaxis remain unclear. A systematic search of PubMed, Embase, and Cochrane central register of controlled trials (CENTRAL) database was conducted from January 1, 2000, to October 30, 2020, including articles addressing treatment with levetiracetam for seizure prophylaxis after SAH, ICH, TBI, and supratentorial neurosurgery. Non-English, pediatric (aged < 18years), preclinical, reviews, case reports, and articles that included patients with a preexisting seizure condition or epilepsy were excluded. The coprimary meta-analyses examined first seizure events in (1) levetiracetam versus no antiseizure medication and (2) levetiracetam versus other antiseizure medications in all ICH, TBI, SAH, and supratentorial neurosurgery populations. Secondary meta-analyses evaluated the same comparator groups in individual disease populations. Risk of bias in non-randomised studies - of interventions (ROBINS-I) and risk-of-bias tool for randomized trials (RoB-2) tools were used to assess risk of bias. A total of 30 studies (n = 6 randomized trials, n = 9 prospective studies, and n = 15 retrospective studies), including 7609 patients (n = 4737 with TBI, n = 701 with SAH, n = 261 with ICH, and n = 1910 with neurosurgical diseases) were included in analyses. Twenty-seven of 30 (90%) studies demonstrated moderate to severe risk of bias, and 11 of 30 (37%) studies used low-dosage levetiracetam (250-500mg twice daily). In the primary meta-analyses, there were no differences in seizure events for levetiracetam prophylaxis (n = 906) versus no antiseizure medication (n = 2728; odds ratio [OR] 0.79, 95% confidence interval [CI] 0.53-1.16, P = 0.23, fixed-effect, I2 = 26%, P = 0.23 for heterogeneity) or levetiracetam (n = 1950) versus other antiseizure prophylaxis (n = 2289; OR 0.84, 95% CI 0.55-1.28, P = 0.41, random-effects, I2 = 49%, P = 0.005 for heterogeneity). Only patients with supratentorial neurosurgical diseases benefited from levetiracetam compared with other antiseizure medications (median 0.70 seizure events per-patient-year with levetiracetam versus 2.20 seizure events per-patient-year for other antiseizure medications, OR 0.34, 95% CI 0.20-0.58, P < 0.001, fixed-effects, I2 = 39%, P = 0.13 for heterogeneity). There were no significant differences in meta-analyses of patients with ICH, SAH, or TBI. Adverse events of any severity were reported in a median of 8% of patients given levetiracetam compared with 21% of patients in comparator groups. Based on the current moderately to seriously biased heterogeneous data, which frequently used low and possibly subtherapeutic doses of levetiracetam, our meta-analyses did not demonstrate significant reductions in seizure incidence and neither supports nor refutes the use of levetiracetam prophylaxis in TBI, SAH, or ICH.Levetiracetam may be preferred post supratentorial neurosurgery.More high-quality randomized trials of prophylactic levetiracetam are warranted.

Psychometric properties of instruments for assessing the methodological quality and risk of bias in non-randomized studies of interventions: a systematic review and meta-analysis in accordance with the COSMIN guideline.